Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

TMB-H 1Melanoma 1Lymphoma, Extranodal NK-T-Cell 1Liver Neoplasms 1

Interventions

pegaspargase 5tislelizumab 2selinexor 2fludarabine phosphate 2Whole-Body Irradiation 2Tacrolimus 2Radiotherapy 2Peripheral Blood Stem Cell Transplantation 2Oxaliplatin 2Mycophenolic Acid 2Gemcitabine 2Etoposide 2Cyclophosphamide 2Busulfan 2Azacitidine 2Asparaginase 2sugemalimab 1relatlimab 1pembrolizumab 1gemcitabine-oxaliplatin regimen 1fludarabine 1Vorinostat 1Valganciclovir 1Transplantation 1Tomography, X-Ray Computed 1Thiotepa 1Therapeutics 1Sirolimus 1Positron-Emission Tomography 1Polymerase Chain Reaction 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma, Extranodal NK-T-Cell × IMC-001 × 1 year × Clear all
NCT04414163 2026-04-24

A Study of IMC-001 in Subjects With Relapsed or Refractory Extranodal NK/T Cell Lymphoma, Nasal Type

ImmuneOncia Therapeutics Inc.

Phase 2 Active not recruiting
23 enrolled
Lymphoid

Lymphoma, Extranodal NK-T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡